Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on X:
“Great to catch up with the amazing Lauren Meehan Machos! Thank you for visiting Nashville, your advocacy and for driving precision oncology forward in ALK, ROS1, and HER2+ cancer. It takes a village to bring cutting-edge care to all patients, and your impact echoes far.”